… who were treated with Lucentis (ranibizumab, Genentech) or Eylea (aflibercept, … the clinical burden on the medical system and patients,” the researchers … confounding retinal conditions and limiting treatment to ranibizumab or aflibercept. Findings showed …

… pivotal randomized controlled trial, showed that ranibizumab was superior to … Pharmaceuticals, Ahmedabad, India) was approved for intravitreal use by the Drug … biosimilar ranibizumab (Razumab, Intas pharmaceuticals, Gujarat, India) in the treatment of …

… , or 0.5 mg ranibizumab, administered via intravitreal injection … said, “While anti-VEGF drugs have helped, 40–60% of … clinical trials When asked how the advancements of the pharmaceutical space … ;3 Clinical Trial for Restoret™ for the Treatment of Diabetic …

… evaluating sura-vec against ranibizumab with a primary endpoint … in the treatment arms. According to the company, the trials have … , chief medical officer of REGENXBIO, commented on the trials in a … 3 clinical trial for sura-vec for the treatment of diabetic …

… extension on patients and medical centers.2 Even … drug that has demonstrated excellent efficacy in both clinical trials … likely attributable to trial conditions, treatment-naïve status, and … outcomes of intravitreal ranibizumab for the treatment of neovascular …

… global, pivotal Phase 3 trials, ATMOSPHERE and ASCENT, evaluating … Steve Pakola, MD, Chief Medical Officer at Regenxbio. “The … of this potentially transformative treatment.” About the Phase 3 … and compares sura-vec to ranibizumab.        • ASCENT includes the …

… Find out more REGENXBIO chief medical officer Steve Pakola said: … of this potentially transformative treatment.” The ATMOSPHERE study in … sura-vec compared to ranibizumab. Meanwhile, ASCENT is … you deserve! The Clinical Trials Arena Excellence Awards celebrate …

… treatment burden. The future of clinical trials must involve the integration of treatment … , et al. Ranibizumab versus verteporfin for … Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema … The RESTORE study: ranibizumab monotherapy or combined …

… Pharmaceutical Co., Ltd.; National Drug Approval Number H20103127). The treatment … Kanghong Biotechnology Co., Ltd.; National Drug Approval … combined with ranibizumab for treatment of diabetic macular … randomized controlled trial. Trials. 2024;25(1 …

… assessment and reflects on potential medico-legal implications supported by current … consent discussions around visual prognosis, treatment options, and systemic risks are … retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology 2014 …